Bausch + LombBLCO
About: Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Employees: 13,300
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
124% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 17
75% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 7 (+3) [Q3]
24% more funds holding
Funds holding: 89 [Q2] → 110 (+21) [Q3]
23% more capital invested
Capital invested by funds: $593M [Q2] → $729M (+$136M) [Q3]
12% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 26
0.88% less ownership
Funds ownership: 11.62% [Q2] → 10.74% (-0.88%) [Q3]
70% less call options, than puts
Call options by funds: $2.68M | Put options by funds: $8.83M
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
B of A Securities Craig Bijou 57% 1-year accuracy 4 / 7 met price target | 0%upside $18 | Underperform Reinstated | 12 Dec 2024 |
HC Wainwright & Co. Yi Chen 39% 1-year accuracy 60 / 154 met price target | 28%upside $23 | Buy Reiterated | 12 Dec 2024 |
Citigroup Joanne Wuensch 55% 1-year accuracy 26 / 47 met price target | 22%upside $22 | Neutral Downgraded | 11 Dec 2024 |
Morgan Stanley Patrick Wood 55% 1-year accuracy 6 / 11 met price target | 6%upside $19 | Equal-Weight Downgraded | 2 Dec 2024 |
Wells Fargo Larry Biegelsen 51% 1-year accuracy 24 / 47 met price target | 44%upside $26 | Overweight Maintained | 31 Oct 2024 |
Financial journalist opinion
